Phase III inTandem1 study of LX 4211 (sotagliflozin) meets secondary endpoints in Type 1 diabetes- Lexicon Pharmaceuticals
Lexicon Pharmaceuticals announced additional positive data from the Phase III inTandem1 study of LX 4211 (sotagliflozin) in Type 1 diabetes. It was previously announced that both doses of sotagliflozin achieved the primary endpoint of the inTandem1 study, showing statistically significant reductions in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized insulin.
New key findings include meaningful benefit of sotagliflozin on body weight in patients with type 1 diabetes and on systolic blood pressure in hypertensive patients with type 1 diabetes. In addition, the Company announced achievement of important secondary endpoints including net benefit, bolus insulin use, fasting plasma glucose and patient reported outcomes.
In a key secondary endpoint, patients taking sotagliflozin experienced a mean reduction from baseline in body weight after 24 weeks of treatment of 1.6 kg for the 200mg dose and 2.7 kg for the 400mg dose, compared to a mean body weight gain of 0.8 kg for patients on placebo. Sustained effects on body weight were also seen at 52 weeks. In addition, systolic blood pressure (SBP) in the subset of type 1 diabetic patients in the study with baseline hypertension (SBP at least 130 mmHg) was reduced by 9.9 mmHg and 11.0 mmHg at week 12 when treated with 200 mg and 400 mg of sotagliflozin, respectively, compared to a reduction of 4.4 mmHg on placebo. Notably, the outcome on every secondary endpoint favored sotagliflozin over placebo, with results for the 400 mg dose having achieved statistical significance for all six secondary endpoints.
Sotagliflozin was generally well tolerated during the 28-week extension period, with rates of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and discontinuations due to AEs that were consistent with rates seen in the initial 24-week treatment period.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.